ESTRELLA IMMUNOPHARMA, INC. (ESLA) Current Ratio
- Current ratio · latest quarter: Value 0.20×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.20× | Current assets / current liabilities. $1.82M ÷ $9.26M ≈ 0.20× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.82M USD | Assets, Current |
| Current obligations | 9.26M USD | Liabilities, Current |
| Cash and equivalents | 100.00K USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.82M | $9.26M | $100.00K | (m) | (m) | (m) | (m) | (m) | 0.20× |
| 2026-03-31 | $2.16M | $8.93M | (m) | (m) | (m) | (m) | (m) | (m) | 0.24× |
| 2025-12-31 | $1.68M | $13.54M | (m) | (m) | (m) | (m) | (m) | (m) | 0.12× |
| 2025-09-30 | $2.02M | $13.36M | $1.63M | (m) | (m) | (m) | (m) | (m) | 0.15× |
| 2025-06-30 | $1.48M | $9.08M | $1.32M | (m) | (m) | (m) | (m) | (m) | 0.16× |
| 2025-03-31 | $944.27K | $4.28M | $421.47K | (m) | (m) | (m) | (m) | (m) | 0.22× |
| 2024-12-31 | $1.64M | $3.00M | $916.92K | (m) | (m) | (m) | (m) | (m) | 0.55× |
| 2024-09-30 | $2.24M | $2.99M | $1.80M | (m) | (m) | (m) | (m) | (m) | 0.75× |
| 2024-06-30 | $4.45M | $180.70K | $4.17M | (m) | (m) | (m) | (m) | (m) | 24.65× |
| 2024-03-31 | $8.63M | $138.49K | $4.73M | (m) | (m) | (m) | (m) | (m) | 62.34× |
| 2023-12-31 | $9.45M | $398.73K | $9.05M | (m) | (m) | (m) | (m) | (m) | 23.69× |
| 2023-06-30 | $2.75M | $9.76M | $2.48M | (m) | (m) | (m) | (m) | (m) | 0.28× |
| 2023-03-31 | $81.89K | $1.22M | $29.39K | (m) | (m) | (m) | (m) | (m) | 0.07× |
| 2022-12-31 | $52.43K | $1.07M | (m) | (m) | (m) | (m) | (m) | (m) | 0.05× |
| 2022-09-30 | $160.75K | $735.75K | $73.75K | (m) | (m) | (m) | (m) | (m) | 0.22× |
| 2022-06-30 | $128.82K | $154.65K | $88.28K | (m) | (m) | (m) | (m) | (m) | 0.83× |
| 2022-03-31 | $428.14K | $30.20K | $321.72K | (m) | (m) | (m) | (m) | (m) | 14.18× |
| 2021-12-31 | $616.03K | $73.15K | $478.87K | (m) | (m) | (m) | (m) | (m) | 8.42× |
| 2021-09-30 | $780.13K | $100.60K | $772.17K | (m) | (m) | (m) | (m) | (m) | 7.75× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |